☆ 4.5 Article

Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis

INVESTIGATIONAL NEW DRUGS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Gastroenterology & Hepatology

Immune checkpoint inhibitor-related cholangiopathy: Novel clinicopathological description of a multi-centre cohort

Philip Berry et al.

Summary: This study investigated bile duct injury in patients receiving immune checkpoint inhibitors (CPI) treatment for malignancy, and found that CPI-related cholangiopathy responded poorly to immunosuppression and potentially progressed to bile duct loss. Thorough radiological and histological assessment is recommended to determine prognosis.

LIVER INTERNATIONAL (2023)

添加到收藏夹

Article Oncology

Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Takafumi Yamamoto et al.

Summary: Liver immune-related adverse events (liver-irAEs) were observed in 42.7% of NSCLC patients treated with ICIs, with a median onset time of 53 days postinjection. Patients with liver-irAEs had significantly worse survival outcomes compared to those without liver-irAEs.

CANCER INVESTIGATION (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Pembrolizumab-related cholangitis with multiple fatal liver abscesses after endoscopic biliary drainage: a case report and review of the literature

Hitomi Hori et al.

Summary: This case report describes a patient with cStage IVB lung cancer who developed pembrolizumab-related cholangitis. Despite biliary drainage, the patient's condition deteriorated and he died from multiple liver abscesses during immunosuppressive therapy.

CLINICAL JOURNAL OF GASTROENTEROLOGY (2022)

添加到收藏夹

Letter Gastroenterology & Hepatology

A case of antiprogrammed death-ligand 1 antibody-induced multisystem immune-related adverse events with pancreatitis and steroid-resistant sclerosing cholangitis

Takafumi Yamamoto et al.

JOURNAL OF DIGESTIVE DISEASES (2022)

添加到收藏夹

Article Oncology

Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer

Yingying Yu et al.

Summary: This study evaluated the clinical biomarkers associated with immune-related adverse events (irAEs) and found that changes in C-reactive protein (CRP), interleukin-6 (IL-6), and lymphocyte subsets were associated with the occurrence of irAEs. Impairments in liver function and routine blood tests were also observed as important indicators of irAEs.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis

Laura Moi et al.

Summary: The study found that targeted therapy focusing on T cells, such as using the IL-6 receptor-neutralizing antibody tocilizumab, can effectively alleviate the severity of the disease in patients with CS-refractory irCH, showing promising therapeutic potential. However, further validation in a larger patient population is necessary.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Inflammatory markers in autoimmunity induced by checkpoint inhibitors

Beate Husain et al.

Summary: This study found that changes in serum levels of IL-6, CRP, and MIA can be used for early detection of immune-related adverse events (irAE) during treatment with immune checkpoint inhibitors, providing guidance for tailored management.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies

Takanori Ito et al.

Summary: The occurrence pattern and therapeutic response to corticosteroids in immune-related liver injury differ according to the injury type, with corticosteroids effective for the hepatocellular pattern but not for refractory non-hepatocellular patterns, indicating the need for additional strategies in such cases.

HEPATOLOGY INTERNATIONAL (2021)

添加到收藏夹

Article Oncology

Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis

Masaki Takinami et al.

Summary: This study compared immune-related sclerosing cholangitis (irSC) and immune-related hepatitis (irHepatitis), finding they have different characteristics in the class of immune checkpoint inhibitors and onset pattern.

INVESTIGATIONAL NEW DRUGS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies

Kazuyuki Mizuno et al.

JOURNAL OF GASTROENTEROLOGY (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review

Takumi Onoyama et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation

Thoetchai (Bee) Peeraphatdit et al.

HEPATOLOGY (2020)

添加到收藏夹

Review Oncology

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance

Emanuel Raschi et al.

TARGETED ONCOLOGY (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors

Eleonora De Martin et al.

JHEP REPORTS (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: Case report and review of published work

Yudai Koya et al.

HEPATOLOGY RESEARCH (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

EASL Clinical Practice Guidelines: Drug-induced liver injury

Raul J. Andrade et al.

JOURNAL OF HEPATOLOGY (2019)

添加到收藏夹

Article Oncology

Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors

Jun Fukihara et al.

CLINICAL LUNG CANCER (2019)

添加到收藏夹

Article Oncology

C-reactive protein as an early marker of immune-related adverse events

Amir-Reza Abolhassani et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Immunotherapy-related hepatitis: real-world experience from a tertiary centre

Vincent Cheung et al.

FRONTLINE GASTROENTEROLOGY (2019)

添加到收藏夹

Review Oncology

A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event

Francesco Gelsomino et al.

INVESTIGATIONAL NEW DRUGS (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors

Eleonora De Martin et al.

JOURNAL OF HEPATOLOGY (2018)

添加到收藏夹

Review Medicine, General & Internal

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Michael A. Postow et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report

Jumpei Kashima et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)

添加到收藏夹

Article Oncology

Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer

Hisato Kawakami et al.

INVESTIGATIONAL NEW DRUGS (2017)

添加到收藏夹

Article Biophysics

Investigation of the freely available easy-to-use software 'EZR' for medical statistics

Y. Kanda

BONE MARROW TRANSPLANTATION (2013)

添加到收藏夹

Article Pharmacology & Pharmacy

Case Definition and Phenotype Standardization in Drug-Induced Liver Injury

G. P. Aithal et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.